
    
      Screening Phase: up to 42 days (consisting of a Screening Visit (V1), a washout period and
      Interim Screening Visit (V1a) when applicable, and a Baseline Visit (V2). The Screening Phase
      will serve multiple purposes: to allow for appropriate washout of prohibited medications; to
      allow for review of screening data; to establish a pre-treatment baseline of key outcome
      measures.

      Treatment Phase: The duration of the treatment is 8 weeks. The purpose of the treatment phase
      is to evaluate the efficacy, safety, tolerability and steady-state plasma trough
      concentration of aripiprazole in the treatment of serious behavioral problems in children and
      adolescents with a diagnosis of Autistic Disorder..

      Safety Follow-up Phase: All subjects will be followed up for safety (adverse events) at Day
      16 after the last medication via telephone.
    
  